Skip to main content
. 2016 Sep 21;6:33569. doi: 10.1038/srep33569

Figure 2. The levels of CSF CXCL13, CXCL10 and CXCL8 were significantly higher in neurosyphilis patients than those in neurosyphilis patients.

Figure 2

(A) The level of CSF CXCL13 in control group (n = 29), non-neurosyphilis patients (including primary, secondary, latent and serofast syphilis; n = 123), neurosyphilis patients (including asymptomatic and symptomatic patients,n = 191). (B) The level of CSF CXCL8 among the samples shown in (A). (C) The level of CSF CXCL10 among the samples shown in (A). (D) The level of serum CXCL13 in control group (n = 63), non-neurosyphilis patients (including primary, secondary, latent and serofast syphilis; n = 111), neurosyphilis patients (including asymptomatic and symptomatic patients, n = 161). (E) The level of serum CXCL10 among the samples shown in (D). (F) The level of serum CXCL10 among the samples shown in (D). (G) The level of CSF CXCL13 in asymptomatic (n = 82) and symptomatic neurosyphilis patients (including meningovascular, paretic, tabetic and ocular, n = 109). (H) The level of CSF CXCL8 among the samples shown in (G). (I) The level of CSF CXCL10 among the samples shown in (G). (J) The level of serum CXCL13 in asymptomatic (n = 69), symptomatic neurosyphilis patients (including meningovascular, paretic, tabetic and ocular, n = 92). (K) The level of serum CXCL10 among the samples shown in (J). (L) The level of serum CXCL10 among the samples shown in (J). (M) The CSF: serum of CXCL13 in non-neurosyphilis patients (including primary, secondary, latent and serofast syphilis; n = 111), neurosyphilis patients (including asymptomatic and symptomatic patients, n = 161). (N) The CSF: serum of CXCL8 among the samples shown in (M). (O) The CSF: serum of CXCL10 among the samples shown in (M). Differences between groups were analyzed by using Mann-Whitney U test.